{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T22:19:55Z","timestamp":1793225995963,"version":"4.5.0"},"reference-count":12,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T00:00:00Z","timestamp":1661904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) have demonstrated promising therapeutic outcomes in treating a variety of malignancies, but immune-related adverse events (irAE) may develop. Among all the irAE, immune-related pneumonitis was relatively common and life-threatening. High-dose corticosteroid was recommended for the initial management, but a part of patients developed steroid-refractory pneumonitis. Other immunosuppressants were recommended, but the optimal treatment is still controversial. Here, we report two cases of steroid-refractory immune-related pneumonitis who were successfully treated with pulse corticosteroid therapy. Case 1 was hepatocellular carcinoma treated with nivolumab for 5 months. She developed acute respiratory distress syndrome due to grade 4 immune-related pneumonitis that was refractory to intravenous methylprednisolone 2 mg\/kg\/day treatment. Methylprednisolone 500 mg for 3 days followed by 2 mg\/kg\/day steroid as maintenance therapy was given. Subsequently, her pneumonitis was regressed, and the endotracheal tube was successfully removed on day 9 after the start of pulse therapy. Case 2 presented with grade 4 immune-related pneumonitis in spite the use of methylprednisolone 1 mg\/kg for his skin rash. Pulse corticosteroid therapy was prescribed, then his pneumonitis was completely regressed on day 12. In this report, we demonstrated the potential role of pulse corticosteroid therapy for steroid-refractory pneumonitis.<\/jats:p>","DOI":"10.3389\/fimmu.2022.994064","type":"journal-article","created":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:30:06Z","timestamp":1661934606000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Pulse corticosteroid therapy in the treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis: Case report and review"],"prefix":"10.3389","volume":"13","author":[{"given":"Kuan-Chang","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Han","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"San-Chi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001731","article-title":"Steroid-refractory PD-(L)1 pneumonitis: Incidence, clinical features, treatment, and outcomes","volume":"9","author":"Balaji","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001884","article-title":"Success and failure of additional immune modulators in steroid-refractory\/resistant pneumonitis related to immune checkpoint blockade","volume":"9","author":"Beattie","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202844","article-title":"Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids","volume":"72","author":"Condon","year":"2013","journal-title":"Ann Rheumatic Diseases"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.622225","article-title":"The use of glucocorticoids in lupus nephritis: New pathways for an old drug","volume":"8","author":"Mej\u00eda-Vilet","year":"2021","journal-title":"Front Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-021-06331-5","article-title":"Immune checkpoint inhibitors-related encephalitis in melanoma and non-melanoma cancer patients: A single center experience","volume":"29","author":"Taliansky","year":"2021","journal-title":"Supportive Care Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.041","article-title":"Myasthenia gravis: An emerging toxicity of immune checkpoint inhibitors","volume":"82","author":"Makarious","year":"2017","journal-title":"Eur J Cancer (Oxford England: 1990)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.34067\/KID.0000152019","article-title":"Acute interstitial nephritis and checkpoint inhibitor therapy","volume":"1","author":"Sandhya Manohar","year":"2020","journal-title":"Kidney360"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/ckj\/sfaa008","article-title":"Acute interstitial nephritis associated with immune checkpoint inhibitors: A single-centre experience","volume":"14","author":"Oleas","year":"2021","journal-title":"Clin Kidney J"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-017-0298-6","article-title":"A case of cystitis after administration of nivolumab","volume":"6","author":"Ozaki","year":"2017","journal-title":"Int Cancer Conf J"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-020-02600-0","article-title":"Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report","volume":"69","author":"Utsumi","year":"2020","journal-title":"Cancer Immunol Immunother: CII"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2019.11.006","article-title":"The safety of pulse corticosteroid therapy- systematic review and meta-analysis","volume":"50","author":"Edel","year":"2020","journal-title":"Semin Arthritis Rheumatism"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.994064\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,31]],"date-time":"2022-08-31T08:30:07Z","timestamp":1661934607000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2022.994064\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,31]]},"references-count":12,"alternative-id":["10.3389\/fimmu.2022.994064"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2022.994064","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,31]]},"article-number":"994064"}}